Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Harvard Business School
Baxter
Medtronic
Boehringer Ingelheim

Last Updated: September 27, 2022

Investigational Drug Information for Tremelimumab


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug Tremelimumab?

Tremelimumab is an investigational drug.

There have been 173 clinical trials for Tremelimumab. The most recent clinical trial was a Phase 3 trial, which was initiated on July 21st 2015.

The most common disease conditions in clinical trials are Carcinoma, Lung Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are AstraZeneca, MedImmune LLC, and National Cancer Institute (NCI).

There are ninety-four US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for Tremelimumab
TitleSponsorPhase
Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)AHS Cancer Control AlbertaPhase 2
Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung CancerAstraZenecaPhase 2
Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung CancerWashington University School of MedicinePhase 2

See all Tremelimumab clinical trials

Clinical Trial Summary for Tremelimumab

Top disease conditions for Tremelimumab
Top clinical trial sponsors for Tremelimumab

See all Tremelimumab clinical trials

US Patents for Tremelimumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Tremelimumab See Plans and Pricing Immunoregulatory agents Flexus Biosciences, Inc. (Princeton, NJ) See Plans and Pricing
Tremelimumab See Plans and Pricing .beta.-glucan methods and compositions that affect the tumor microenvironment BIOTHERA, INC. (Eagan, MN) See Plans and Pricing
Tremelimumab See Plans and Pricing Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Harvard Business School
Baxter
Medtronic
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.